CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSureĀ® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMapĀ® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/
View Top Employees from CareDx, Inc.Website | http://www.caredx.com |
Ticker | CDNA |
Revenue | $308.4 million |
Funding | $98.5 million |
Employees | 693 (693 on RocketReach) |
Founded | 1998 |
Address | 8000 Marina Blvd, Brisbane, California 94005, US |
Phone | (415) 287-2300 |
Fax | (415) 287-2450 |
Industry | Biotechnology Research, Medical Testing & Clinical Laboratories, Diagnostic Equipment, Diagnostics, Healthcare, Transplant Patient Care |
Web Rank | 4 Million |
Keywords | Caredx, Caredx Inc, Honor The Gift Caredx, Caredx Board Of Directors, Caredx Analyst Coverage |
Competitors | Castle Biosciences, Inc., Chronix Biomedical, Inc., Great Basin Scientific, Inc., Lineagen, Veracyte, Inc. |
SIC | SIC Code 38 Companies, SIC Code 37 Companies |
NAICS | NAICS Code 62151 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 621 Companies, NAICS Code 541711 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 6215 Companies, NAICS Code 62 Companies |
Looking for a particular CareDx, Inc. employee's phone or email?
The CareDx, Inc. annual revenue was $308.4 million in 2024.
Abhishek Jain is the CFO of CareDx, Inc..
693 people are employed at CareDx, Inc..
CareDx, Inc. is based in Brisbane, California.
The NAICS codes for CareDx, Inc. are [62151, 54171, 54, 621, 541711, 5417, 541, 6215, 62].
The SIC codes for CareDx, Inc. are [38, 37].